Back

GSK plans September Phase 3 launch for mRNA flu vaccine after strong results

Verifying
  • GSK selected FLUm3HA.b-3NA for a September Phase 3 seasonal flu vaccine trial.
  • Flu-028 evaluated 971 adults aged 18 and older for 181 days.
  • FDA granted the candidate Fast Track designation in July 2026 for targeted age groups.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.